내시경적 점막 하층 박리술(ESD) 시장 : 시장 예측(2026-2032년)

The Endoscopic Submucosal Dissection Market is projected to grow by USD 662.51 million at a CAGR of 6.13% by 2032.

Endoscopic submucosal dissection is an advanced, organ-preserving endoscopic resection technique used to remove selected superficial gastrointestinal neoplasia in one piece, enabling precise histopathology, margin assessment, and potentially curative treatment without conventional surgery. The clinical relevance is reinforced by the global burden of lesions that may enter an ESD evaluation pathway: in 2022, colorectal cancer accounted for 1,926,425 new cases worldwide, stomach cancer for 968,784, and oesophageal cancer for 511,054. Current clinical guidance supports ESD as a first-option approach for many superficial esophageal squamous and gastric lesions and as a selective en bloc strategy for colorectal, particularly rectal, lesions with features suggesting limited submucosal invasion.

For industry stakeholders, the ESD landscape is defined less by broad procedural availability and more by the convergence of early cancer detection, high-definition endoscopic imaging, expert training, pathology readiness, anesthesia support, and multidisciplinary decision-making.

Transformative Shifts in the ESD Landscape

The ESD landscape is shifting from procedure-centric adoption toward integrated early-cancer pathways. Clinical guidance has elevated ESD because it can deliver en bloc resection and accurate staging in lesions where piecemeal removal risks incomplete pathology, while surveillance pathways after curative ESD increasingly rely on high-definition white-light endoscopy and chromoendoscopy rather than routine cross-sectional staging for low-risk resections.

A second transformation is the move from opportunistic expertise to structured competency development. International survey evidence shows that real-world ESD training remains constrained by time and access: limited training time was rated a major barrier by 55.3% of respondents in Asia-Pacific, 48.6% in Southeast Europe, 41.7% in Africa and the Middle East, 36.0% in the Americas, and 21.0% in Northwest Europe. This underlines a central operational shift: successful ESD programs require protected training, supervised progression, simulation, complication management, referral triage, and outcomes documentation.

A third shift is lesion-selection discipline. ESD is gaining strategic importance where clinicians must balance curative intent, accurate staging, recurrence prevention, patient preference, and surgical avoidance. The strongest adopters are building pathways that connect screening, optical diagnosis, lesion mapping, resection planning, specimen handling, pathology review, and surveillance in a single quality framework.

Cumulative Impact of Artificial Intelligence in ESD

Artificial intelligence is reshaping ESD indirectly and cumulatively by improving the upstream detection and characterization of lesions that may be referred for advanced resection. In randomized-trial meta-analysis of AI-assisted colonoscopy, the pooled adenoma detection rate was higher with computer-aided detection than standard colonoscopy, at 41.4% versus 33.0%, with a relative risk of 1.26. This matters for ESD because better identification of flat, nonpolypoid, scarred, laterally spreading, or suspicious lesions can improve referral quality and reduce inappropriate piecemeal treatment.

AI is also moving into upper-GI decision support. Systematic review evidence in early upper gastrointestinal cancer reported pooled patient-based performance for AI-assisted diagnosis with an AUC of 0.95, sensitivity of 0.95, and specificity of 0.82, while gastric-focused reviews describe applications in early lesion detection, invasion-depth assessment, margin delineation, classification, and segmentation. These capabilities support the ESD workflow by strengthening pre-resection risk stratification, video documentation, training feedback, and multidisciplinary review, though they do not replace expert optical diagnosis, pathology, or operator competency.

The cumulative impact is a more data-rich ESD ecosystem: AI can expand the pool of detected lesions, standardize quality indicators, support remote case review, and help training programs analyze procedural video. The key leadership challenge is governance, including validating algorithms locally, preventing over-referral of clinically insignificant findings, maintaining human accountability, and aligning AI outputs with guideline-based ESD indications.

Key Regional Insights: Asia-Pacific, North America, Latin America, Europe, Middle East, and Africa

Asia-Pacific remains the most clinically influential region for endoscopic submucosal dissection because the burden of early gastric, colorectal, and esophageal neoplasia is concentrated across large populations and mature endoscopy ecosystems. China reported 517,106 colorectal, 358,672 stomach, and 224,012 oesophageal cancer cases in 2022, while Japan reported 145,756 colorectal and 126,724 stomach cancer cases, and South Korea reported colorectal and stomach cancers among its top three cancer sites. India adds a different burden profile, with oesophageal cancer at 70,637 cases, colorectal cancer at 70,038, and stomach cancer at 64,611 in 2022. These patterns make Asia-Pacific a priority for high-quality lesion detection, gastric ESD, colorectal ESD, esophageal ESD, and structured advanced endoscopy training.

North America is characterized by strong colorectal cancer screening infrastructure and growing interest in organ-preserving advanced resection. The United States recorded 160,186 colorectal cancer cases in 2022, with stomach and oesophageal cancers at 25,554 and 18,747, respectively; Canada recorded 23,725 colorectal cancer cases, with stomach and oesophageal cancers at 4,113 and 3,136. The region's ESD priorities center on expert-center access, payer-aligned referral pathways, North American guideline adoption, and training models that help transition appropriate lesions from surgery or piecemeal endoscopic mucosal resection to en bloc ESD where clinically justified.

Latin America shows rising relevance for ESD through concentrated colorectal and upper-GI disease in major referral systems. Brazil reported 60,118 colorectal, 23,021 stomach, and 10,985 oesophageal cancer cases in 2022, while Mexico reported 16,082 colorectal, 9,516 stomach, and 1,433 oesophageal cancer cases. The region's near-term opportunity lies in centralizing complex ESD cases, improving early diagnosis, strengthening pathology turnaround, and building bilingual or regional training networks that allow advanced endoscopists to progress safely.

Europe combines high colorectal burden, guideline-driven practice, and strong cross-border clinical education. The United Kingdom, Germany, France, Russia, Italy, and Spain each reported substantial colorectal cancer case counts in 2022, with 49,429, 62,544, 51,636, 83,693, 54,784, and 39,421 cases, respectively, making colorectal ESD, rectal ESD, and advanced lesion triage central themes. European guidance supports ESD for selected superficial GI lesions and provides a foundation for harmonized quality measures, surveillance, and training.

The Middle East is developing as a selective, tertiary-care ESD environment where advanced endoscopy programs must align specialist availability with upper-GI cancer risk, anesthesia capacity, and pathology support. Regional planning is strengthened by the fact that neighboring West Asian disease patterns include high stomach cancer relevance, with Iran listed among the countries with the highest stomach cancer incidence in 2022. For Middle Eastern health systems, ESD readiness depends on referral governance, complication rescue capability, and physician training rather than simple equipment availability.

Africa's ESD trajectory is closely linked to early detection capacity. Oesophageal cancer incidence has been reported as particularly high in Eastern and Southern Africa, yet ESD can only deliver its full clinical value when lesions are identified while still superficial. Training constraints are material: Africa and the Middle East together reported limited available training time as a major barrier in 41.7% of survey responses. The region's priority is therefore a stepwise pathway from diagnostic endoscopy access and pathology infrastructure to regional centers of excellence capable of safe ESD.

Key Group Insights: ASEAN, GCC, European Union, BRICS, G7, and NATO

ASEAN represents a heterogeneous ESD opportunity shaped by uneven screening coverage, variable endoscopy capacity, and growing upper-GI and colorectal diagnostic needs. Southeast Asian systems can improve access by linking national cancer-control programs to referral centers, particularly where gastric cancer remains visible in regional data, such as Vietnam's 16,277 stomach cancer cases in 2022. The most effective ASEAN strategy is likely to combine diagnostic quality improvement, expert mentoring, standardized lesion documentation, and regional case conferences rather than attempting immediate broad-based ESD diffusion.

GCC health systems are positioned to adopt ESD through tertiary hospitals, multidisciplinary oncology programs, and high-acuity endoscopy services. The strategic focus should be on guideline-based lesion selection, physician credentialing, adverse-event response, and integration with pathology and surgical backup. Because ESD is highly skill dependent, GCC leaders should emphasize durable training partnerships, simulation, and outcomes registries before expanding case volumes.

The European Union benefits from guideline alignment, colorectal screening maturity, and dense specialist networks, making it a natural environment for standardized ESD quality indicators. Germany, France, Italy, and Spain together show large colorectal cancer burdens, while European guidance supports ESD for selected superficial esophageal, gastric, Barrett's-associated, and colorectal lesions. EU priorities include interoperable training curricula, cross-border referral pathways for complex cases, and evidence-based surveillance after curative resection.

BRICS and expanded BRICS economies create one of the largest clinically relevant ESD platforms because the grouping includes countries with major absolute burdens of colorectal, stomach, and oesophageal cancer. Official BRICS information lists the original members with newer members admitted in 2024-2025, including Egypt, Ethiopia, Indonesia, Iran, Saudi Arabia, and the United Arab Emirates; within the original high-burden members, China, India, Brazil, and Russia alone show substantial ESD-relevant case loads across colorectal and upper-GI cancers.

G7 countries combine advanced endoscopy infrastructure with large ageing populations and high diagnostic intensity. The United States, Canada, Japan, the United Kingdom, Germany, France, and Italy all show meaningful colorectal cancer burdens, while Japan's stomach cancer burden remains especially important for gastric ESD expertise. G7 priorities include competency-based training, AI-enabled detection governance, appropriate reimbursement logic, and consistent reporting of en bloc, R0, curative resection, recurrence, and adverse events.

NATO is not a healthcare purchasing or clinical-governance bloc, but its overlap with North American and European health systems makes it relevant for resilience thinking, workforce mobility, training exchange, and hospital readiness. Since NATO's membership framework is political and security-oriented, ESD stakeholders should treat the grouping as a proxy for shared high-income infrastructure in many member states rather than as a direct clinical channel.

Key Country Insights Across Major ESD-Relevant Healthcare Systems

In North America, the United States is the anchor ESD opportunity because colorectal cancer ranked among the country's top cancers with 160,186 cases in 2022, while stomach and oesophageal cancers added 25,554 and 18,747 cases; Canada's profile is smaller but similar, with 23,725 colorectal, 4,113 stomach, and 3,136 oesophageal cases. Mexico adds a different access dynamic, reporting 16,082 colorectal and 9,516 stomach cancer cases, making referral-center development and early lesion recognition important for safe ESD expansion.

In Latin America, Brazil is the key country driver, with 60,118 colorectal, 23,021 stomach, and 10,985 oesophageal cancer cases in 2022. Its ESD priorities include concentrating expertise in advanced endoscopy centers, linking screening colonoscopy to lesion triage, and formalizing referral criteria so patients with superficial lesions are evaluated for organ-preserving resection before surgical escalation.

In Europe, the United Kingdom recorded 49,429 colorectal, 9,601 oesophageal, and 6,034 stomach cancer cases in 2022; Germany recorded 62,544 colorectal, 14,088 stomach, and 7,310 oesophageal cases; France recorded 51,636 colorectal, 7,673 stomach, and 4,942 oesophageal cases; Russia recorded 83,693 colorectal, 38,883 stomach, and 9,345 oesophageal cases; Italy recorded 54,784 colorectal and 13,501 stomach cases; and Spain recorded 39,421 colorectal and 7,173 stomach cases. These country profiles make colorectal ESD, rectal lesion management, and upper-GI expert pathways important across Western, Southern, and Eastern Europe.

In Asia-Pacific, China represents the largest absolute ESD-relevant burden, with 517,106 colorectal, 358,672 stomach, and 224,012 oesophageal cancer cases in 2022, while India reported 70,637 oesophageal, 70,038 colorectal, and 64,611 stomach cases. Japan remains central to gastric and colorectal ESD expertise, reporting 145,756 colorectal, 126,724 stomach, and 19,926 oesophageal cases; Australia's ESD relevance is led by colorectal cancer, with 17,088 cases and lower stomach and oesophageal counts of 2,837 and 1,755; and South Korea reported colorectal and stomach cancers as its second and third most frequent cancers, with 29,560 and 29,267 cases.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize clinically governed ESD ecosystems rather than isolated procedural expansion. First, build referral pathways that identify lesions appropriate for en bloc resection before piecemeal removal compromises pathology. Second, support competency-based training that includes optical diagnosis, simulated dissection, supervised procedures, bleeding and perforation management, specimen orientation, and surveillance planning. Third, align digital documentation and AI-assisted detection with clinical governance so that AI improves lesion recognition and triage without weakening human accountability. Fourth, invest in outcomes registries that track en bloc resection, R0 resection, curative resection, recurrence, adverse events, procedure time, and need for additional surgery. Fifth, focus regional strategy on high-burden countries and expert centers where early diagnosis, pathology, anesthesia, and rescue surgery can be reliably coordinated. These recommendations align with published guidance emphasizing ESD for selected superficial GI lesions and with evidence that training capacity remains a major real-world barrier.

Research Methodology

This executive summary was developed using a structured evidence-synthesis approach focused on verified clinical and epidemiological sources. The analysis prioritized international clinical guidance for ESD indications and curative-resection criteria, peer-reviewed systematic reviews on AI-assisted endoscopy, and population-level cancer incidence, mortality, and prevalence data from recognized cancer registry-based sources. Country and regional insights were triangulated across 2022 cancer burden estimates for colorectal, stomach, and oesophageal cancers, because these disease areas most directly shape the clinical funnel for endoscopic submucosal dissection.

The methodology deliberately excludes market estimation, market sizing, market share, and forecasting. Instead, it evaluates burden of disease, guideline alignment, training constraints, procedural readiness, AI-enabled diagnostic shifts, and health-system infrastructure. Conclusion: ESD as a Core Capability in Organ-Preserving GI Cancer Care

Endoscopic submucosal dissection is becoming a defining capability in advanced therapeutic endoscopy because it connects early cancer detection with organ-preserving, pathology-rich treatment. Its adoption is strongest where screening, high-quality imaging, expert training, pathology, anesthesia, and multidisciplinary governance work together. Asia-Pacific leads through high upper-GI and colorectal disease burden and mature ESD expertise; North America and Europe are advancing through guidelines, colorectal screening, and expert-center models; Latin America, the Middle East, and Africa show meaningful opportunities where early detection and training infrastructure are strengthened.

The next phase of ESD will be shaped by disciplined lesion selection, structured training, AI-assisted detection, outcomes transparency, and regional referral networks. Leaders that focus on clinical quality, access, and evidence-based workflows will be best positioned to support safe, scalable, and patient-centered ESD adoption without relying on speculative commercial metrics.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
    • 4.3.1.1. Earlier Lesion Detection Expands the Treatable Pool for Organ-Preserving Resection
    • 4.3.1.2. Organ-Preservation Economics Strengthen the Hospital Business Case
    • 4.3.1.3. Integrated Visualization and Therapeutic Tools Improve Procedural Confidence
    • 4.3.1.4. Guideline Support Converts Specialist Practice into Institutional Adoption
  • 4.3.2. Key Restraints
    • 4.3.2.1. Operator Scarcity Limits Conversion from Clinical Need to Procedure Volume
    • 4.3.2.2. Reimbursement and Procedure-Time Economics Pressure Hospital Adoption
  • 4.3.3. Key Opportunities
    • 4.3.3.1. Convert Fragmented Consumables into Indication-Specific ESD Kits
    • 4.3.3.2. Attach AI Workflow Software to Premium Endoscopy Platforms
    • 4.3.3.3. Use Traction and Robotic Assistance to Reduce Procedure Complexity
  • 4.3.4. Key Challenges
    • 4.3.4.1. Scale Clinical Capability Before Device Availability Outpaces Operator Readiness
    • 4.3.4.2. Navigate Regulated Regionalization Without Sacrificing Margin or Market Access
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Endoscopic Submucosal Dissection Market, by Product

• 7.1. Introduction
• 7.2. Endoscopes
  • 7.2.1. Colonoscopes
  • 7.2.2. Duodenoscopes
  • 7.2.3. Gastroscopes
• 7.3. ESD Knives
  • 7.3.1. Dual Knife
  • 7.3.2. IT Knife
  • 7.3.3. Hook Knife
  • 7.3.4. Needle Knife
• 7.4. Injection Needles
• 7.5. Hemostasis Devices
  • 7.5.1. Coagulation Forceps
  • 7.5.2. Hemostatic Forceps
• 7.6. Tissue Retraction Devices
• 7.7. Accessory Devices
  • 7.7.1. Cap & Hood
  • 7.7.2. Insufflations Units
  • 7.7.3. Trocars

8. Endoscopic Submucosal Dissection Market, by Procedure Type

• 8.1. Introduction
• 8.2. Full-Thickness Resection
• 8.3. Hybrid ESD
• 8.4. Partial-Thickness Resection

9. Endoscopic Submucosal Dissection Market, by Indication Type

• 9.1. Introduction
• 9.2. Colorectal Cancer
• 9.3. Esophageal Cancer
• 9.4. Gastric Cancer
• 9.5. Precancerous Lesions

10. Endoscopic Submucosal Dissection Market, by Disease Condition

• 10.1. Introduction
• 10.2. Benign Tumors
• 10.3. Malignant Tumors
  • 10.3.1. Invasive
  • 10.3.2. Non-Invasive

11. Endoscopic Submucosal Dissection Market, by End-User Type

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Hospitals
• 11.4. Specialty Clinics

12. Endoscopic Submucosal Dissection Market, by Region

• 12.1. Asia-Pacific
• 12.2. Europe
• 12.3. North America
• 12.4. Latin America
• 12.5. Middle East
• 12.6. Africa

13. Endoscopic Submucosal Dissection Market, by Group

• 13.1. NATO
• 13.2. G7
• 13.3. BRICS
• 13.4. European Union
• 13.5. ASEAN
• 13.6. GCC

14. Endoscopic Submucosal Dissection Market, by Country

• 14.1. China
• 14.2. United States
• 14.3. Japan
• 14.4. Germany
• 14.5. South Korea
• 14.6. India
• 14.7. France
• 14.8. United Kingdom
• 14.9. Italy
• 14.10. Canada
• 14.11. Brazil
• 14.12. Australia
• 14.13. Mexico
• 14.14. Russia
• 14.15. Spain

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Olympus Corporation
• 16.2. Fujifilm Holdings Corporation
• 16.3. Boston Scientific Corporation
• 16.4. Erbe Elektromedizin GmbH
• 16.5. PENTAX Medical by Hoya Corporation
• 16.6. MICRO-TECH (Nanjing) Co., Ltd.
• 16.7. Medtronic PLC
• 16.8. Cook Group Incorporated
• 16.9. Sumitomo Bakelite Co., Ltd.
• 16.10. ConMed Corporation
• 16.11. Karl Storz SE & Co. KG
• 16.12. Ovesco Endoscope AG
• 16.13. STERIS plc
• 16.14. Hangzhou AGS MedTech Co., Ltd.
• 16.15. Medi-Globe GmbH by DCC Healthcare
• 16.16. Aohua Endoscopy Co., Ltd.
• 16.17. Anrei Medical (Hangzhou) Co., Ltd.
• 16.18. Leo Medical Co. Ltd.
• 16.19. Seikagaku Corporation
• 16.20. Creo Medical Group plc
• 16.21. Jiangsu Vedkang Medical Science and Technology Co., Ltd.
• 16.22. MTW-Endoskopie W. Haag KG
• 16.23. Cosmo Pharmaceuticals N.V.
• 16.24. GI Supply, Inc.
• 16.25. Zeon Medical Co., Ltd.
• 16.26. Endo-Flex GmbH by Medi-Globe Group
• 16.27. Lumendi AG
• 16.28. Upexmed Co., Ltd.
• 16.29. Actuated Medical, Inc.
• 16.30. Agilis Robotics Limited
• 16.31. Ambu A/S
• 16.32. ATRACT Device & Co.
• 16.33. Beijing ZKSK Technology Co., Ltd.
• 16.34. Flexicare Medical Ltd.
• 16.35. Interscope, Inc.
• 16.36. Kachu Technology Co., Ltd.
• 16.37. Neptune Medical Inc.
• 16.38. Richard Wolf GmbH
• 16.39. Sunarrow Co., Ltd.
• 16.40. TOP Corporation
• 16.41. Zhejiang Soudon Medical Technology Co., Ltd.